Company Filing History:
Years Active: 2020
Title: A Ari Hakimi: Innovator in Cancer Therapeutics
Introduction
A Ari Hakimi is a prominent inventor based in New Rochelle, NY (US). He has made significant contributions to the field of cancer research, particularly in the development of biomarkers for evaluating therapeutic responses to rapamycin analogs. His work is crucial in understanding how certain genetic mutations can influence treatment outcomes in cancer patients.
Latest Patents
A Ari Hakimi holds a patent titled "Biomarkers for response to rapamycin analogs." This invention relates to the use of one or more biomarkers to assess the likelihood that a rapamycin analog would produce an anti-cancer effect in a subject. The patent is based on experiments that utilized an integrated next-generation sequencing approach to analyze spatially separated tumor specimens from the same individuals. This research aimed to decipher intra-tumor and intertumor heterogeneity and determine the oncogenomic basis of exceptional therapeutic benefits to rapalogs in kidney cancer patients. The findings indicated that loss of function mutations in TSC1 and/or TSC2 and/or gain-of-function of mTOR are critical in therapeutic responsiveness to rapamycin analogs. The invention provides assay methods and kits for detecting these mutations, which can aid in selecting appropriate therapeutic regimens for cancer patients.
Career Highlights
A Ari Hakimi is affiliated with the Memorial Sloan Kettering Cancer Center, where he continues to advance cancer research and treatment methodologies. His innovative work has positioned him as a key figure in the field of oncology, particularly in the context of personalized medicine.
Collaborations
Throughout his career, A Ari Hakimi has collaborated with notable colleagues, including James Hsieh and Michael Berger. These collaborations have further enriched his research and contributed to the advancement of cancer therapeutics.
Conclusion
A Ari Hakimi's contributions to cancer research through his innovative patent on biomarkers for rapamycin analogs exemplify the importance of personalized medicine in oncology. His work not only enhances our understanding of cancer treatment but also paves the way for more effective therapeutic strategies.